Testosterone Replacement for Male Opioid Agonist Maintained Patients

• Status: Completed
• Trial end date: 2015-01-01
• Target enrollment: 0
• Participant gender: Male

Summary

This study is designed to develop an effective treatment intervention for chronic pain, symptomatic hypogonadism, and opioid addiction

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yale University
• Treatments: Analgesics, Opioid; Methyltestosterone; Testosterone; Testosterone 17 beta-cypionate; Testosterone enanthate; Testosterone undecanoate

Criteria

Inclusion Criteria:

• Between 18 and 50 years of age

• Male buprenorphine- or methadone-maintained patients at the APT Foundation

• Moderate to severe chronic pain

• Meet criteria for symptomatic hypogonadism

• Understand English

• Interested in receiving testosterone replacement

Exclusion Criteria:

• Current suicide or homicide risk

• Life-threatening or unstable medical condition

• Known or suspected prostate or chest cancer or history of polycythemia